Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.07
AMED's Cash to Debt is ranked higher than
56% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 0.23 vs. AMED: 0.07 )
AMED' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.07

Equity to Asset 0.50
AMED's Equity to Asset is ranked higher than
75% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. AMED: 0.50 )
AMED' s 10-Year Equity to Asset Range
Min: -0.31   Max: 1
Current: 0.5

-0.31
1
F-Score: 4
Z-Score: 1.32
M-Score: -3.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -12.40
AMED's Operating margin (%) is ranked higher than
50% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 9.44 vs. AMED: -12.40 )
AMED' s 10-Year Operating margin (%) Range
Min: -100.58   Max: 15.25
Current: -12.4

-100.58
15.25
Net-margin (%) -7.70
AMED's Net-margin (%) is ranked higher than
53% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 4.97 vs. AMED: -7.70 )
AMED' s 10-Year Net-margin (%) Range
Min: -97.66   Max: 9.33
Current: -7.7

-97.66
9.33
ROE (%) -25.84
AMED's ROE (%) is ranked lower than
52% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 8.44 vs. AMED: -25.84 )
AMED' s 10-Year ROE (%) Range
Min: -73.71   Max: 162.77
Current: -25.84

-73.71
162.77
ROA (%) -13.24
AMED's ROA (%) is ranked lower than
51% of the 235 Companies
in the Global Medical Care industry.

( Industry Median: 3.63 vs. AMED: -13.24 )
AMED' s 10-Year ROA (%) Range
Min: -55.98   Max: 11.59
Current: -13.24

-55.98
11.59
ROC (Joel Greenblatt) (%) -97.45
AMED's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 16.84 vs. AMED: -97.45 )
AMED' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -316.4   Max: 333.68
Current: -97.45

-316.4
333.68
Revenue Growth (%) -10.70
AMED's Revenue Growth (%) is ranked higher than
52% of the 200 Companies
in the Global Medical Care industry.

( Industry Median: 7.00 vs. AMED: -10.70 )
AMED' s 10-Year Revenue Growth (%) Range
Min: -26.1   Max: 35.1
Current: -10.7

-26.1
35.1
» AMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

AMED Guru Trades in Q2 2013

Charles Brandes 228,880 sh (+1.33%)
Paul Tudor Jones Sold Out
» More
Q3 2013

AMED Guru Trades in Q3 2013

Charles Brandes 229,165 sh (+0.12%)
» More
Q4 2013

AMED Guru Trades in Q4 2013

Charles Brandes 215,640 sh (-5.9%)
» More
Q1 2014

AMED Guru Trades in Q1 2014

Jim Simons 144,680 sh (New)
Charles Brandes 165,125 sh (-23.43%)
» More
» Details

Insider Trades

Latest Guru Trades with AMED

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2014-03-31 Reduce -23.43%0.01%$14.09 - $16.96 $ 16.417%165125
Charles Brandes 2013-03-31 Add 515.74%0.03%$10.95 - $13.11 $ 16.4141%225885
Joel Greenblatt 2012-12-31 Sold Out 0.06%$9.65 - $13.56 $ 16.4145%0
Charles Brandes 2012-12-31 New Buy$9.65 - $13.56 $ 16.4145%36685
Joel Greenblatt 2012-09-30 Reduce -49.75%0.06%$11.3 - $15.84 $ 16.4120%65015
Charles Brandes 2012-09-30 Sold Out 0.0017%$11.3 - $15.84 $ 16.4120%0
John Hussman 2012-06-30 Sold Out 0.04%$9.87 - $15.03 $ 16.4132%0
Joel Greenblatt 2012-03-31 Add 98.71%0.09%$9.56 - $14.66 $ 16.4149%144813
Charles Brandes 2012-03-31 New Buy$9.56 - $14.66 $ 16.4149%20195
David Dreman 2011-12-31 Sold Out 0.5%$9.59 - $14.56 $ 16.4140%0
George Soros 2011-12-31 Sold Out 0.0041%$9.59 - $14.56 $ 16.4140%0
Charles Brandes 2011-12-31 Sold Out 0.0021%$9.59 - $14.56 $ 16.4140%0
Joel Greenblatt 2011-09-30 Add 125.99%0.09%$13.29 - $27.55 $ 16.41-17%64379
George Soros 2011-09-30 Reduce -91.93%0.07%$13.29 - $27.55 $ 16.41-17%16100
Ronald Muhlenkamp 2011-06-30 Sold Out 1.15%$25.28 - $35.18 $ 16.41-47%0
George Soros 2011-06-30 New Buy0.07%$25.28 - $35.18 $ 16.41-47%199599
Joel Greenblatt 2011-06-30 Add 21.45%0.02%$25.28 - $35.18 $ 16.41-47%28488
Charles Brandes 2011-06-30 New Buy$25.28 - $35.18 $ 16.41-47%14350
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.40
AMED's P/B is ranked higher than
90% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 2.80 vs. AMED: 1.40 )
AMED' s 10-Year P/B Range
Min: 0.5   Max: 6.34
Current: 1.4

0.5
6.34
P/S 0.40
AMED's P/S is ranked higher than
94% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 1.64 vs. AMED: 0.40 )
AMED' s 10-Year P/S Range
Min: 0.19   Max: 2.36
Current: 0.4

0.19
2.36
PFCF 19.80
AMED's PFCF is ranked higher than
82% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 32.98 vs. AMED: 19.80 )
AMED' s 10-Year PFCF Range
Min: 2.96   Max: 89.91
Current: 19.8

2.96
89.91
EV-to-EBIT -3.01
AMED's EV-to-EBIT is ranked lower than
57% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 26.54 vs. AMED: -3.01 )
AMED' s 10-Year EV-to-EBIT Range
Min: 3   Max: 21
Current: -3.01

3
21
Current Ratio 0.63
AMED's Current Ratio is ranked higher than
52% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 1.40 vs. AMED: 0.63 )
AMED' s 10-Year Current Ratio Range
Min: 0.33   Max: 2.88
Current: 0.63

0.33
2.88
Quick Ratio 0.63
AMED's Quick Ratio is ranked higher than
53% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 1.24 vs. AMED: 0.63 )
AMED' s 10-Year Quick Ratio Range
Min: 0.31   Max: 2.85
Current: 0.63

0.31
2.85

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.30
AMED's Price/Tangible Book is ranked higher than
79% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 8.44 vs. AMED: 4.30 )
AMED' s 10-Year Price/Tangible Book Range
Min: 0.35   Max: 2380
Current: 4.3

0.35
2380
Price/DCF (Projected) 0.40
AMED's Price/DCF (Projected) is ranked higher than
98% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 3.72 vs. AMED: 0.40 )
AMED' s 10-Year Price/DCF (Projected) Range
Min: 0.16   Max: 4.75
Current: 0.4

0.16
4.75
Price/Median PS Value 0.40
AMED's Price/Median PS Value is ranked higher than
99% of the 258 Companies
in the Global Medical Care industry.

( Industry Median: 1.27 vs. AMED: 0.40 )
AMED' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 2.15
Current: 0.4

0.09
2.15
Earnings Yield (Greenblatt) 13.10
AMED's Earnings Yield (Greenblatt) is ranked higher than
95% of the 225 Companies
in the Global Medical Care industry.

( Industry Median: 5.40 vs. AMED: 13.10 )
AMED' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.8   Max: 33.7
Current: 13.1

4.8
33.7
Forward Rate of Return (Yacktman) 22.82
AMED's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 203 Companies
in the Global Medical Care industry.

( Industry Median: 10.68 vs. AMED: 22.82 )
AMED' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -21.7   Max: 103.2
Current: 22.82

-21.7
103.2

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Traded in other countries:ADY.Germany
Amedisys, Inc., was originally incorporated in Louisiana in 1982. Its operations were transferred to a Delaware corporation, which was incorporated in 1994; and became a publicly traded company in August of that year. The Company is a health care company engaged in delivering personalized health care services to patients and their families. Its chronic care management programs and innovative technology infrastructure enable it to deliver quality care based upon the latest evidence-based best practices. It also has one of the industry's first nationwide Care Transitions program. Its Care Transitions is designed to reduce unnecessary hospital readmissions through patient and caregiver health coaching and care coordination, which starts in the hospital and continues through completion of the patient's home health plan of care. As of December 31, 2011, it owned and operated 435 Medicare-certified home health care centers, 97 Medicare-certified hospice care centers and two hospice inpatient units in 38 states within the United States, the District of Columbia and Puerto Rico. Its services are mainly paid for by Medicare due to the age demographics of its patient base (average age 81). The Company is subject to Federal, state and local laws and regulations.
» More Articles for AMED

Headlines

Articles On GuruFocus.com
comment on AMED Jun 20 2012 
well undervalued, st Jan 24 2012 
“Powerball” Ideas - Home Healthcare Companies: AFAM, GTIV, LHCG, AMED Jan 05 2012 
AMED: Investment Opportunity When the Price Hits an 8-Year Low Dec 27 2011 
Almost Family: The Magic Formula Stock is getting cheaper and cheaper Dec 11 2011 
guru bargain Oct 05 2011 
Magic Formula Stock: Amedisys (AMED) Aug 05 2011 
Home Healthcare: Heavily Shorted long Opportunity May 30 2011 
Amedisys Inc (AMED) CFO Dale E Redman buys 1,000 Shares Aug 25 2010 
Amedisys Inc Reports Operating Results (10-Q) Aug 09 2010 

More From Our Partners
Gentiva (GTIV) Worth Watching: Stock Gains 16.1% - Tale of the Tape Jul 21 2014 - ZACKS

More From Other Websites
DaVita's Domestic Acquisitions Look Good, Debt Lingers Jul 18 2014
Universal Health Services (UHS) Jumps: Stock Up 5.6% Jul 17 2014
Earnings Estimates Moving Higher for Amedisys (AMED): Time to Buy? Jul 10 2014
Amedisys Announces Completion of SEC Investigation Jul 08 2014
[$$] Amedisys Says No SEC Enforcement Action Planned Jul 08 2014
AMEDISYS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jul 08 2014
Amedisys Announces Completion of SEC Investigation Jul 08 2014
Kindred urges Gentiva shareholders to vote for buyout offer Jul 01 2014
Amedisys (AMED) Highlighted As Today's Perilous Reversal Stock Jun 30 2014
Can the Uptrend Continue for Amedisys (AMED)? Jun 30 2014
Kindred Healthcare sends letter to Gentiva Health board Jun 27 2014
Stocks Mildly Higher To End The Week Jun 27 2014
Midday movers: Dollar General, DuPont, Nike & More Jun 27 2014
Why Amedisys (AMED) Stock Is Gaining Today Jun 27 2014
Amedisys Previews Second Quarter 2014 Results Jun 27 2014
Amedisys Previews Second Quarter 2014 Results Jun 27 2014
AMEDISYS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide